Targeting BRD9 for Cancer Treatment: A New Strategy

References

• Savas S, Skardasi G. The SWI/SNF complex subunit genes: their functions, variations, and links to risk and survival outcomes in human cancers. Crit Rev Oncol Hematol. 2018;123:114–131. doi:10.1016/j.critrevonc.2018.01.00929482773
   PubMed Web of Science ®Google Scholar
• Masliah-Planchon J, Bieche I, Guinebretiere JM, Bourdeaut F, Delattre O. SWI/SNF chromatin remodeling and human malignancies. Annu Rev Pathol. 2015;10:145–171. doi:10.1146/annurev-pathol-012414-04044525387058
   PubMed Web of Science ®Google Scholar
• Wu JI, Lessard J, Crabtree GR. Understanding the words of chromatin regulation. Cell. 2009;136(2):200–206. doi:10.1016/j.cell.2009.01.00919167321
   PubMed Web of Science ®Google Scholar
• Kadoch C, Hargreaves DC, Hodges C, et al. Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet. 2013;45(6):592–601. doi:10.1038/ng.262823644491
   PubMed Web of Science ®Google Scholar
• Calderaro J, Masliah-Planchon J, Richer W, et al. Balanced translocations disrupting SMARCB1 are hallmark recurrent genetic alterations in renal medullary carcinomas. Eur Urol. 2016;69(6):1055–1061. doi:10.1016/j.eururo.2015.09.02726433572
   PubMed Web of Science ®Google Scholar
• Bruggers CS, Bleyl SB, Pysher T, et al. Clinicopathologic comparison of familial versus sporadic atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system. Pediatr Blood Cancer. 2011;56(7):1026–1031. doi:10.1002/pbc.2275720848638
   PubMed Web of Science ®Google Scholar
• Eaton KW, Tooke LS, Wainwright LM, Judkins AR, Biegel JA. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. Pediatr Blood Cancer. 2011;56(1):7–15. doi:10.1002/pbc.2283121108436
   PubMed Web of Science ®Google Scholar
• Ammerlaan AC, Ararou A, Houben MP, et al. Long-term survival and transmission of INI1-mutation via nonpenetrant males in a family with rhabdoid tumour predisposition syndrome. Br J Cancer. 2008;98(2):474–479. doi:10.1038/sj.bjc.660415618087273
   PubMed Web of Science ®Google Scholar
• Trobaugh-Lotrario AD, Tomlinson GE, Finegold MJ, Gore L, Feusner JH. Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors. Pediatr Blood Cancer. 2009;52(3):328–334. doi:10.1002/pbc.2183418985717
   PubMed Web of Science ®Google Scholar
• Ho AS, Kannan K, Roy DM, et al. The mutational landscape of adenoid cystic carcinoma. Nat Genet. 2013;45(7):791–798. doi:10.1038/ng.264323685749
   PubMed Web of Science ®Google Scholar
• Love C, Sun Z, Jima D, et al. The genetic landscape of mutations in burkitt lymphoma. Nat Genet. 2012;44(12):1321–1325.23143597
   PubMed Web of Science ®Google Scholar
• Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150(6):1107–1120. doi:10.1016/j.cell.2012.08.02922980975
   PubMed Web of Science ®Google Scholar
• Dulak AM, Stojanov P, Peng S, et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. 2013;45(5):478–486. doi:10.1038/ng.259123525077
   PubMed Web of Science ®Google Scholar
• Parsons DW, Li M, Zhang X, et al. The genetic landscape of the childhood cancer medulloblastoma. Science. 2011;331(6016):435–439. doi:10.1126/science.119805621163964
   PubMed Web of Science ®Google Scholar
• Pugh TJ, Weeraratne SD, Archer TC, et al. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012;488(7409):106–110. doi:10.1038/nature1132922820256
   PubMed Web of Science ®Google Scholar
• Jones DT, Jager N, Kool M, et al. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012;488(7409):100–105. doi:10.1038/nature1128422832583
   PubMed Web of Science ®Google Scholar
• Guichard C, Amaddeo G, Imbeaud S, et al. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat Genet. 2012;44(6):694–698. doi:10.1038/ng.225622561517
   PubMed Web of Science ®Google Scholar
• Wang K, Kan J, Yuen ST, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011;43(12):1219–1223. doi:10.1038/ng.98222037554
   PubMed Web of Science ®Google Scholar
• Zang ZJ, Cutcutache I, Poon SL, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. 2012;44(5):570–574. doi:10.1038/ng.224622484628
   PubMed Web of Science ®Google Scholar
• Gui Y, Guo G, Huang Y, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nat Genet. 2011;43(9):875–878. doi:10.1038/ng.90721822268
   PubMed Web of Science ®Google Scholar
• Guo G, Sun X, Chen C, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nature Genetics. 2013;45(12):1459–1463. doi:10.1038/ng.279824121792
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas N. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–337. doi:10.1038/nature1125222810696
   PubMed Web of Science ®Google Scholar
• Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399–405. doi:10.1038/nature1154723103869
   PubMed Web of Science ®Google Scholar
• Jiao Y, Pawlik TM, Anders RA, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45(12):1470–1473. doi:10.1038/ng.281324185509
   PubMed Web of Science ®Google Scholar
• Wang X, Wang S, Troisi EC, et al. BRD9 defines a SWI/SNF sub-complex and constitutes a specific vulnerability in malignant rhabdoid tumors. Nat Commun. 2019;10(1):1881. doi:10.1038/s41467-019-09891-731015438
   PubMed Web of Science ®Google Scholar
• Alpsoy A, Dykhuizen EC. Glioma tumor suppressor candidate region gene 1 (GLTSCR1) and its paralog GLTSCR1-like form SWI/SNF chromatin remodeling subcomplexes. J Biol Chem. 2018;293(11):3892–3903. doi:10.1074/jbc.RA117.00106529374058
   PubMed Web of Science ®Google Scholar
• Hohmann AF, Martin LJ, Minder JL, et al. Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition. Nat Chem Biol. 2016;12(9):672–679. doi:10.1038/nchembio.211527376689
   PubMed Web of Science ®Google Scholar
• Kang JU, Koo SH, Kwon KC, Park JW, Kim JM. Gain at chromosomal region 5p15.33, containing TERT, is the most frequent genetic event in early stages of non-small cell lung cancer. Cancer Genet Cytogenet. 2008;182(1):1–11. doi:10.1016/j.cancergencyto.2007.12.00418328944
   PubMedGoogle Scholar
• Yang C, Xu W, Gong J, Liu Z, Cui D. Novel somatic alterations underlie Chinese papillary thyroid carcinoma. Cancer Biomark. 2020;27(4):445–460. doi:10.3233/CBM-19120032065787
   PubMed Web of Science ®Google Scholar
• Scotto L, Narayan G, Nandula SV, et al. Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. Mol Cancer. 2008;7:58. doi:10.1186/1476-4598-7-5818559093
   PubMed Web of Science ®Google Scholar
• Banito A, Li X, Laporte AN, et al. The SS18-SSX oncoprotein hijacks KDM2B-PRC1.1 to drive synovial sarcoma. Cancer Cell. 2018;33(3):527–541.e528. doi:10.1016/j.ccell.2018.01.01829502955
   PubMed Web of Science ®Google Scholar
• Brien GL, Remillard D, Shi J, et al. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. Elife. 2018:7. doi:10.7554/eLife.41305
   Web of Science ®Google Scholar
• McBride MJ, Pulice JL, Beird HC, et al. The SS18-SSX fusion oncoprotein hijacks BAF complex targeting and function to drive synovial sarcoma. Cancer Cell. 2018;33(6):1128–1141.e1127. doi:10.1016/j.ccell.2018.05.00229861296
   PubMed Web of Science ®Google Scholar
• Middeljans E, Wan X, Jansen PW, Sharma V, Stunnenberg HG, Logie C. SS18 together with animal-specific factors defines human BAF-type SWI/SNF complexes. PLoS One. 2012;7(3):e33834. doi:10.1371/journal.pone.003383422442726
   PubMed Web of Science ®Google Scholar
• Ashcroft FM, Rorsman P. Diabetes mellitus and the beta cell: the last ten years. Cell. 2012;148(6):1160–1171. doi:10.1016/j.cell.2012.02.01022424227
   PubMed Web of Science ®Google Scholar
• Donath MY, Dalmas E, Sauter NS, Boni-Schnetzler M. Inflammation in obesity and diabetes: islet dysfunction and therapeutic opportunity. Cell Metab. 2013;17(6):860–872. doi:10.1016/j.cmet.2013.05.00123747245
   PubMed Web of Science ®Google Scholar
• Halban PA, Polonsky KS, Bowden DW, et al. beta-cell failure in type 2 diabetes: postulated mechanisms and prospects for prevention and treatment. Diabetes Care. 2014;37(6):1751–1758. doi:10.2337/dc14-039624812433
   PubMed Web of Science ®Google Scholar
• Wei Z, Yoshihara E, He N, et al. Vitamin D switches BAF complexes to protect beta cells. Cell. 2018;173(5):1135–1149 e1115. doi:10.1016/j.cell.2018.04.01329754817
   PubMed Web of Science ®Google Scholar
• Sima X, He J, Peng J, Xu Y, Zhang F, Deng L. The genetic alteration spectrum of the SWI/SNF complex: the oncogenic roles of BRD9 and ACTL6A. PLoS One. 2019;14(9):e0222305. doi:10.1371/journal.pone.022230531504061
   PubMed Web of Science ®Google Scholar
• Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64–69. doi:10.1038/nature1049621909114
   PubMed Web of Science ®Google Scholar
• Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365(15):1384–1395. doi:10.1056/NEJMoa110328321995386
   PubMed Web of Science ®Google Scholar
• Wang L, Lawrence MS, Wan Y, et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med. 2011;365(26):2497–2506. doi:10.1056/NEJMoa110901622150006
   PubMed Web of Science ®Google Scholar
• Seiler M, Peng S, Agrawal AA, et al. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep. 2018;23(1):282–296.e284.29617667
   PubMed Web of Science ®Google Scholar
• Inoue D, Chew GL, Liu B, et al. Spliceosomal disruption of the non-canonical BAF complex in cancer. Nature. 2019;574(7778):432–436. doi:10.1038/s41586-019-1646-931597964
   PubMed Web of Science ®Google Scholar
• Campos C, Fragoso S, Luís R, et al. High-throughput sequencing identifies 3 novel susceptibility genes for hereditary melanoma. Genes (Basel). 2020;11(4):403.
   PubMed Web of Science ®Google Scholar
• Park DE, Cheng J, McGrath JP, et al. Merkel cell polyomavirus activates LSD1-mediated blockade of non-canonical BAF to regulate transformation and tumorigenesis. Nat Cell Biol. 2020;22(5):603–615. doi:10.1038/s41556-020-0503-232284543
   PubMed Web of Science ®Google Scholar
• Waddington CH. Preliminary notes on the development of the wings in normal and mutant strains of Drosophila. Proc Natl Acad Sci U S A. 1939;25(7):299–307. doi:10.1073/pnas.25.7.29916577903
   PubMedGoogle Scholar
• Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693–705. doi:10.1016/j.cell.2007.02.00517320507
   PubMed Web of Science ®Google Scholar
• Wolffe AP, Matzke MA. Epigenetics: regulation through repression. Science. 1999;286(5439):481–486. doi:10.1126/science.286.5439.48110521337
   PubMed Web of Science ®Google Scholar
• Perez-Salvia M, Esteller M. Bromodomain inhibitors and cancer therapy: from structures to applications. Epigenetics. 2017;12(5):323–339. doi:10.1080/15592294.2016.126571027911230
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Picaud S, Mangos M, et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell. 2012;149(1):214–231. doi:10.1016/j.cell.2012.02.01322464331
   PubMed Web of Science ®Google Scholar
• Sanchez R, Zhou -M-M. The role of human bromodomains in chromatin biology and gene transcription. Curr Opin Drug Discov Devel. 2009;12(5):659–665.
   PubMedGoogle Scholar
• Celic I, Masumoto H, Griffith WP, et al. The sirtuins hst3 and Hst4p preserve genome integrity by controlling histone h3 lysine 56 deacetylation. Curr Biol. 2006;16(13):1280–1289. doi:10.1016/j.cub.2006.06.02316815704
   PubMed Web of Science ®Google Scholar
• Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 2000;19(6):1176–1179. doi:10.1093/emboj/19.6.117610716917
   PubMed Web of Science ®Google Scholar
• Jenuwein T, Allis CD. Translating the histone code. Science. 2001;293(5532):1074–1080. doi:10.1126/science.106312711498575
   PubMed Web of Science ®Google Scholar
• Choudhary C, Kumar C, Gnad F, et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science. 2009;325(5942):834–840. doi:10.1126/science.117537119608861
   PubMed Web of Science ®Google Scholar
• Zhao S, Xu W, Jiang W, et al. Regulation of cellular metabolism by protein lysine acetylation. Science. 2010;327(5968):1000–1004. doi:10.1126/science.117968920167786
   PubMed Web of Science ®Google Scholar
• Dhalluin C, Carlson JE, Zeng L, He C, Aggarwal AK, Zhou MM. Structure and ligand of a histone acetyltransferase bromodomain. Nature. 1999;399(6735):491–496. doi:10.1038/2097410365964
   PubMed Web of Science ®Google Scholar
• Owen DJ, Ornaghi P, Yang JC, et al. The structural basis for the recognition of acetylated histone H4 by the bromodomain of histone acetyltransferase gcn5p. EMBO J. 2000;19(22):6141–6149. doi:10.1093/emboj/19.22.614111080160
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Knapp S. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat Rev Drug Discov. 2014;13(5):337–356. doi:10.1038/nrd428624751816
   PubMed Web of Science ®Google Scholar
• Poplawski A, Hu K, Lee W, et al. Molecular insights into the recognition of N-terminal histone modifications by the BRPF1 bromodomain. J Mol Biol. 2014;426(8):1661–1676. doi:10.1016/j.jmb.2013.12.00724333487
   PubMed Web of Science ®Google Scholar
• Demont EH, Bamborough P, Chung CW, et al. 1,3-dimethyl benzimidazolones are potent, selective inhibitors of the BRPF1 bromodomain. ACS Med Chem Lett. 2014;5(11):1190–1195. doi:10.1021/ml500293225408830
   PubMed Web of Science ®Google Scholar
• Burke TW, Cook JG, Asano M, Nevins JR. Replication factors MCM2 and ORC1 interact with the histone acetyltransferase HBO1. J Biol Chem. 2001;276(18):15397–15408. doi:10.1074/jbc.M01155620011278932
   PubMed Web of Science ®Google Scholar
• Leachman NT, Brellier F, Ferralli J, Chiquet-Ehrismann R, Tucker RP. ATAD2B is a phylogenetically conserved nuclear protein expressed during neuronal differentiation and tumorigenesis. Dev Growth Differ. 2010;52(9):747–755. doi:10.1111/j.1440-169X.2010.01211.x21158754
   PubMed Web of Science ®Google Scholar
• Caron C, Lestrat C, Marsal S, et al. Functional characterization of ATAD2 as a new cancer/testis factor and a predictor of poor prognosis in breast and lung cancers. Oncogene. 2010;29(37):5171–5181. doi:10.1038/onc.2010.25920581866
   PubMed Web of Science ®Google Scholar
• Ciro M, Prosperini E, Quarto M, et al. ATAD2 is a novel cofactor for MYC, overexpressed and amplified in aggressive tumors. Cancer Res. 2009;69(21):8491–8498. doi:10.1158/0008-5472.CAN-09-213119843847
   PubMed Web of Science ®Google Scholar
• Poncet-Montange G, Zhan Y, Bardenhagen JP, et al. Observed bromodomain flexibility reveals histone peptide- and small molecule ligand-compatible forms of ATAD2. Biochem J. 2015;466(2):337–346. doi:10.1042/BJ2014093325486442
   PubMedGoogle Scholar
• Koo SJ, Fernandez-Montalvan AE, Badock V, et al. ATAD2 is an epigenetic reader of newly synthesized histone marks during DNA replication. Oncotarget. 2016;7(43):70323–70335. doi:10.18632/oncotarget.1185527612420
   PubMedGoogle Scholar
• Zou JX, Guo L, Revenko AS, et al. Androgen-induced coactivator ANCCA mediates specific androgen receptor signaling in prostate cancer. Cancer Res. 2009;69(8):3339–3346. doi:10.1158/0008-5472.CAN-08-344019318566
   PubMed Web of Science ®Google Scholar
• Crawford TD, Tsui V, Flynn EM, et al. Diving into the water: inducible binding conformations for BRD4, TAF1(2), BRD9, and CECR2 bromodomains. J Med Chem. 2016;59(11):5391–5402. doi:10.1021/acs.jmedchem.6b0026427219867
   PubMed Web of Science ®Google Scholar
• Harte MT, O’Brien GJ, Ryan NM, et al. BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription. Cancer Res. 2010;70(6):2538–2547. doi:10.1158/0008-5472.CAN-09-208920215511
   PubMed Web of Science ®Google Scholar
• Flynn EM, Huang OW, Poy F, et al. A subset of human bromodomains recognizes butyryllysine and crotonyllysine histone peptide modifications. Structure. 2015;23(10):1801–1814. doi:10.1016/j.str.2015.08.00426365797
   PubMed Web of Science ®Google Scholar
• Helin K, Dhanak D. Chromatin proteins and modifications as drug targets. Nature. 2013;502(7472):480–488. doi:10.1038/nature1275124153301
   PubMed Web of Science ®Google Scholar
• Fujisawa T, Filippakopoulos P. Functions of bromodomain-containing proteins and their roles in homeostasis and cancer. Nat Rev Mol Cell Biol. 2017;18(4):246–262. doi:10.1038/nrm.2016.14328053347
   PubMed Web of Science ®Google Scholar
• Del Gaudio N, Di Costanzo A, Liu NQ, et al. BRD9 binds cell type-specific chromatin regions regulating leukemic cell survival via STAT5 inhibition. Cell Death Dis. 2019;10(5):338. doi:10.1038/s41419-019-1570-931000698
   PubMedGoogle Scholar
• Carow B, Rottenberg ME. SOCS3, a major regulator of infection and inflammation. Front Immunol. 2014;5:58. doi:10.3389/fimmu.2014.0005824600449
   PubMed Web of Science ®Google Scholar
• Agger K, Miyagi S, Pedersen MT, Kooistra SM, Johansen JV, Helin K. Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells. Genes Dev. 2016;30(11):1278–1288. doi:10.1101/gad.280495.11627257215
   PubMed Web of Science ®Google Scholar
• Ferbeyre G, Moriggl R. The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochim Biophys Acta. 2011;1815(1):104–114. doi:10.1016/j.bbcan.2010.10.00420969928
   PubMed Web of Science ®Google Scholar
• Lin JX, Leonard WJ. The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene. 2000;19(21):2566–2576. doi:10.1038/sj.onc.120352310851055
   PubMed Web of Science ®Google Scholar
• Furqan M, Akinleye A, Mukhi N, Mittal V, Chen Y, Liu D. STAT inhibitors for cancer therapy. J Hematol Oncol. 2013;6:90.24308725
   PubMed Web of Science ®Google Scholar
• The L. Lung cancer: some progress, but still a lot more to do. Lancet. 2019;394(10212):1880.
   Web of Science ®Google Scholar
• Brinkmeyer JK, Moore DC. Necitumumab for the treatment of squamous cell non-small cell lung cancer. J Oncol Pharm Pract. 2018;24(1):37–41. doi:10.1177/107815521668236527913776
   PubMed Web of Science ®Google Scholar
• Travis WD, Brambilla E, Nicholson AG, et al. The 2015 World Health Organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification. J Thorac Oncol. 2015;10(9):1243–1260. doi:10.1097/JTO.000000000000063026291008
   PubMed Web of Science ®Google Scholar
• Xue X, Fei X, Hou W, Zhang Y, Liu L, Hu R. miR-342-3p suppresses cell proliferation and migration by targeting AGR2 in non-small cell lung cancer. Cancer Lett. 2018;412:170–178. doi:10.1016/j.canlet.2017.10.02429107102
   PubMed Web of Science ®Google Scholar
• Chen D, Guo W, Qiu Z, et al. MicroRNA-30d-5p inhibits tumour cell proliferation and motility by directly targeting CCNE2 in non-small cell lung cancer. Cancer Lett. 2015;362(2):208–217. doi:10.1016/j.canlet.2015.03.04125843294
   PubMed Web of Science ®Google Scholar
• Langsch S, Baumgartner U, Haemmig S, et al. miR-29b mediates NF-kappaB Signaling in KRAS-induced non-small cell lung cancers. Cancer Res. 2016;76(14):4160–4169. doi:10.1158/0008-5472.CAN-15-258027199349
   PubMed Web of Science ®Google Scholar
• Huang H, Wang Y, Li Q, Fei X, Ma H, Hu R. miR-140-3p functions as a tumor suppressor in squamous cell lung cancer by regulating BRD9. Cancer Lett. 2019;446:81–89. doi:10.1016/j.canlet.2019.01.00730660651
   PubMed Web of Science ®Google Scholar
• Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170(4):605–635.28802037
   PubMed Web of Science ®Google Scholar
• Samuels Y, Wang Z, Bardelli A, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554. doi:10.1126/science.109650215016963
   PubMed Web of Science ®Google Scholar
• Yaeger R, Chatila WK, Lipsyc MD, et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell. 2018;33(1):125–136e123. doi:10.1016/j.ccell.2017.12.00429316426
   PubMed Web of Science ®Google Scholar
• Campbell JD, Alexandrov A, Kim J, et al. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet. 2016;48(6):607–616. doi:10.1038/ng.356427158780
   PubMed Web of Science ®Google Scholar
• Razavi P, Chang MT, Xu G, et al. The genomic landscape of endocrine-resistant advanced breast cancers. Cancer Cell. 2018;34(3):427–438e426.30205045
   PubMed Web of Science ®Google Scholar
• Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):pl1. doi:10.1126/scisignal.200408823550210
   PubMed Web of Science ®Google Scholar
• Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–404. doi:10.1158/2159-8290.CD-12-009522588877
   PubMed Web of Science ®Google Scholar
• Ramjaun AR, Downward J. Ras and phosphoinositide 3-kinase: partners in development and tumorigenesis. Cell Cycle. 2007;6(23):2902–2905. doi:10.4161/cc.6.23.499617993782
   PubMed Web of Science ®Google Scholar
• Bell CM, Raffeiner P, Hart JR, Vogt PK. PIK3CA cooperates with KRAS to promote MYC activity and tumorigenesis via the bromodomain protein BRD9. Cancers (Basel). 2019;11(11):1634. doi:10.3390/cancers11111634
   PubMed Web of Science ®Google Scholar
• Muller S, Filippakopoulos P, Knapp S. Bromodomains as therapeutic targets. Expert Rev Mol Med. 2011;13:e29. doi:10.1017/S146239941100199221933453
   PubMed Web of Science ®Google Scholar
• Hewings DS, Rooney TP, Jennings LE, et al. Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions. J Med Chem. 2012;55(22):9393–9413. doi:10.1021/jm300915b22924434
   PubMed Web of Science ®Google Scholar
• Filippakopoulos P, Qi J, Picaud S, et al. Selective inhibition of BET bromodomains. Nature. 2010;468(7327):1067–1073. doi:10.1038/nature0950420871596
   PubMed Web of Science ®Google Scholar
• Hewings DS, Wang M, Philpott M, et al. 3,5-dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J Med Chem. 2011;54(19):6761–6770. doi:10.1021/jm200640v21851057
   PubMed Web of Science ®Google Scholar
• Picaud S, Da Costa D, Thanasopoulou A, et al. PFI-1, a highly selective protein interaction inhibitor, targeting BET Bromodomains. Cancer Res. 2013;73(11):3336–3346. doi:10.1158/0008-5472.CAN-12-329223576556
   PubMed Web of Science ®Google Scholar
• Krämer KF, Moreno N, Frühwald MC, Kerl K. BRD9 inhibition, alone or in combination with cytostatic compounds as a therapeutic approach in rhabdoid tumors. Int J Mol Sci. 2017;18(7):1537. doi:10.3390/ijms18071537
   PubMed Web of Science ®Google Scholar
• Bevill SM, Olivares-Quintero JF, Sciaky N, et al. GSK2801, a BAZ2/BRD9 bromodomain inhibitor, synergizes with BET inhibitors to induce apoptosis in triple-negative breast cancer. Mol Cancer Res. 2019;17(7):1503–1518. doi:10.1158/1541-7786.MCR-18-112131000582
   PubMed Web of Science ®Google Scholar
• Su J, Liu X, Zhang S, Yan F, Zhang Q, Chen J. Insight into selective mechanism of class of I-BRD9 inhibitors toward BRD9 based on molecular dynamics simulations. Chem Biol Drug Des. 2019;93(2):163–176. doi:10.1111/cbdd.1339830225973
   PubMed Web of Science ®Google Scholar
• Martin LJ, Koegl M, Bader G, et al. Structure-based design of an in vivo active selective BRD9 inhibitor. J Med Chem. 2016;59(10):4462–4475. doi:10.1021/acs.jmedchem.5b0186526914985
   PubMed Web of Science ®Google Scholar
• Karim RM, Schonbrunn E. An advanced tool to interrogate BRD9. J Med Chem. 2016;59(10):4459–4461. doi:10.1021/acs.jmedchem.6b0055027120693
   PubMed Web of Science ®Google Scholar
• Karim RM, Chan A, Zhu JY, Schönbrunn E. Structural basis of inhibitor selectivity in the BRD7/9 Subfamily of Bromodomains. J Med Chem. 2020;63(6):3227–3237. doi:10.1021/acs.jmedchem.9b0198032091206
   PubMed Web of Science ®Google Scholar
• Clegg MA, Bamborough P, Chung CW, et al. Application of atypical acetyl-lysine methyl mimetics in the development of selective inhibitors of the Bromodomain-Containing Protein 7 (BRD7)/Bromodomain-Containing Protein 9 (BRD9) Bromodomains. J Med Chem. 2020;63(11):5816–5840. doi:10.1021/acs.jmedchem.0c0007532410449
   PubMed Web of Science ®Google Scholar
• Clark PG, Vieira LC, Tallant C, et al. LP99: discovery and synthesis of the first selective BRD7/9 Bromodomain inhibitor. Angew Chem Int Ed Engl. 2015;54(21):6217–6221. doi:10.1002/anie.20150139425864491
   PubMed Web of Science ®Google Scholar
• Crawford TD, Vartanian S, Cote A, et al. Inhibition of bromodomain-containing protein 9 for the prevention of epigenetically-defined drug resistance. Bioorg Med Chem Lett. 2017;27(15):3534–3541. doi:10.1016/j.bmcl.2017.05.06328606761
   PubMed Web of Science ®Google Scholar
• Zhao D, Mo Y, Li MT, et al. NOTCH-induced aldehyde dehydrogenase 1A1 deacetylation promotes breast cancer stem cells. J Clin Invest. 2014;124(12):5453–5465. doi:10.1172/JCI7661125384215
   PubMed Web of Science ®Google Scholar
• Rice KL, Izon DJ, Ford J, Boodhoo A, Kees UR, Greene WK. Overexpression of stem cell associated ALDH1A1, a target of the leukemogenic transcription factor TLX1/HOX11, inhibits lymphopoiesis and promotes myelopoiesis in murine hematopoietic progenitors. Leuk Res. 2008;32(6):873–883. doi:10.1016/j.leukres.2007.11.00118082256
   PubMed Web of Science ®Google Scholar
• Theodoulou NH, Bamborough P, Bannister AJ, et al. Discovery of I-BRD9, a selective cell active chemical probe for Bromodomain containing protein 9 inhibition. J Med Chem. 2016;59(4):1425–1439. doi:10.1021/acs.jmedchem.5b0025625856009
   PubMed Web of Science ®Google Scholar
• Yan Y, Zhang L, Xu T, et al. SAMSN1 is highly expressed and associated with a poor survival in glioblastoma multiforme. PLoS One. 2013;8(11):e81905. doi:10.1371/journal.pone.008190524278465
   PubMed Web of Science ®Google Scholar
• Sattler S, Reiche D, Sturtzel C, et al. The human C-type lectin-like receptor CLEC-1 is upregulated by TGF-beta and primarily localized in the endoplasmic membrane compartment. Scand J Immunol. 2012;75(3):282–292. doi:10.1111/j.1365-3083.2011.02665.x22117783
   PubMed Web of Science ®Google Scholar
• Zhang S, Chitu V, Stanley ER, Elliott BE, Greer PA. Fes tyrosine kinase expression in the tumor niche correlates with enhanced tumor growth, angiogenesis, circulating tumor cells, metastasis, and infiltrating macrophages. Cancer Res. 2011;71(4):1465–1473. doi:10.1158/0008-5472.CAN-10-375721159660
   PubMed Web of Science ®Google Scholar
• Bagnyukova TV, Restifo D, Beeharry N, et al. DUSP6 regulates drug sensitivity by modulating DNA damage response. Br J Cancer. 2013;109(4):1063–1071. doi:10.1038/bjc.2013.35323839489
   PubMed Web of Science ®Google Scholar
• Zheng P, Zhang J, Ma H, et al. Design, synthesis and biological evaluation of imidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD9 inhibitors. Bioorg Med Chem. 2019;27(7):1391–1404. doi:10.1016/j.bmc.2019.02.04530824168
   PubMed Web of Science ®Google Scholar
• Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. 2017;16(2):101–114. doi:10.1038/nrd.2016.21127885283
   PubMed Web of Science ®Google Scholar
• Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature. 2010;468(7327):1119–1123. doi:10.1038/nature0958921068722
   PubMed Web of Science ®Google Scholar
• Remillard D, Buckley DL, Paulk J, et al. Degradation of the BAF complex factor BRD9 by heterobifunctional ligands. Angew Chem Int Ed Engl. 2017;56(21):5738–5743. doi:10.1002/anie.20161128128418626
   PubMed Web of Science ®Google Scholar
• Zoppi V, Hughes SJ, Maniaci C, et al. Iterative design and optimization of initially inactive Proteolysis Targeting Chimeras (PROTACs) Identify VZ185 as a potent, fast, and selective von Hippel-Lindau (VHL) based dual degrader probe of BRD9 and BRD7. J Med Chem. 2019;62(2):699–726. doi:10.1021/acs.jmedchem.8b0141330540463
   PubMed Web of Science ®Google Scholar
• Michel BC, D’Avino AR, Cassel SH, et al. A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation. Nat Cell Biol. 2018;20(12):1410–1420. doi:10.1038/s41556-018-0221-130397315
   PubMed Web of Science ®Google Scholar